203522-62-7

Basic information

• Product Name: 1-(4-chlorophenylsulphonyl)-4-[1-(2-methylpyrimidin-4-yl)piperazin-4-ylcarbonyl]piperidine
• Synonyms: 1-(4-chlorophenylsulphonyl)-4-[1-(2-methylpyrimidin-4-yl)piperazin-4-ylcarbonyl]piperidine
• CAS NO: 203522-62-7
• Molecular Weight: 463.988
• Mol File: 203522-62-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(4-chlorophenylsulphonyl)-4-[1-(2-methylpyrimidin-4-yl)piperazin-4-ylcarbonyl]piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chlorophenylsulphonyl)-4-[1-(2-methylpyrimidin-4-yl)piperazin-4-ylcarbonyl]piperidine(203522-62-7)
• EPA Substance Registry System: 1-(4-chlorophenylsulphonyl)-4-[1-(2-methylpyrimidin-4-yl)piperazin-4-ylcarbonyl]piperidine(203522-62-7)

Safety Data

• Hazardous Substances Data: 203522-62-7(Hazardous Substances Data)

Upstream product

• 4994-86-9 4-chloro-2-methylpyrimidine 

Relevant articles and documents

Substituted pyrimidine derivatives and their pharmaceutical use

PCT No. PCT/GB97/02029 Sec. 371 Date Feb. 12, 1999 Sec. 102(e) Date Feb. 12, 1999 PCT Filed Jul. 25, 1997 PCT Pub. No. WO98/06705 PCT Pub. Date Feb. 19, 1998This invention concerns heterocyclic derivatives which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.